ReviewJournal of movement disorders2016
Clinical Approach to Progressive Supranuclear Palsy.
Review in Journal of movement disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Application of Deep Brain Stimulation for Progressive Supranuclear Palsy: A Systematic Review.Frontiers in neurology · 2022Pooled it
- Clinical patterns in social cognition & personality changes in progressive supranuclear palsy.Journal of neurology · 2026Article
- Spectrum of Dystonia in Progressive Supranuclear Palsy: A Prospective Observational Study and Review of Literature.Tremor and other hyperkinetic movements (New York, N.Y.) · 2026Observational
- Cognitive and neuropsychiatric profiles distinguish atypical parkinsonian syndromes.Brain : a journal of neurology · 2025Article
- Tau P301S Transgenic Mice Develop Gait and Eye Movement Impairments That Mimic Progressive Supranuclear Palsy.bioRxiv : the preprint server for biology · 2024Article
- SEND-PD in Parkinsonian Syndromes: Results of a Monocentric Cross-Sectional Study.Neuropsychiatric disease and treatment · 2024Article
- Efficacy of faecal microbiota transplantation in patients with progressive supranuclear palsy-Richardson's syndrome: a phase 2, single centre, randomised clinical trial.EClinicalMedicine · 2023Article
- Clinical features of progressive supranuclear palsy.Frontiers in aging neuroscience · 2023Article
- Clinical Aspects of the Differential Diagnosis of Parkinson's Disease and Parkinsonism.Journal of clinical neurology (Seoul, Korea) · 2022Review
- "Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Review
- MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology.Annals of clinical and translational neurology · 2021Article
- The Genetic Landscape of Parkinsonism-Related Dystonias and Atypical Parkinsonism-Related Syndromes.International journal of molecular sciences · 2021Review
- Article
- Genetics of Progressive Supranuclear Palsy: A Review.Journal of Parkinson's disease · 2021Review
- Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.Frontiers in neurology · 2021Review
- Phenotypic Variants of Patients with Progressive Supranuclear Palsy.Noro psikiyatri arsivi · 2020Article
- Tauopathy and Movement Disorders-Unveiling the Chameleons and Mimics.Frontiers in neurology · 2020Review
- Prediction of the Clinical Severity of Progressive Supranuclear Palsy by Diffusion Tensor Imaging.Journal of clinical medicine · 2019Article
- Revisiting the diagnostic value of Evans' index: lessons from an unusual case of normal pressure hydrocephalus with Evans' index less than 0.3.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Article
- Clinical Milestones Preceding the Diagnosis of Multiple System Atrophy and Progressive Supranuclear Palsy: A Retrospective Cohort Study.Journal of movement disorders · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sixty years ago, Steele, Richardson and Olszewski designated progressive supranuclear palsy (PSP) as a new clinicopathological entity in their seminal paper. Since then, in addition to the classic Richardson's syndrome (RS), different clinical phenotypic presentations have been linked with this four-repeat tauopathy. The clinical heterogeneity is associated with variability of regional distribution and severity of abnormal tau accumulation and neuronal loss. In PSP subtypes, the presence of certain clinical pointers may be useful for antemortem prediction of the underlying PSP-tau pathology. Midbrain atrophy on conventional MRI correlates with the clinical phenotype of RS but is not predictive of PSP pathology. Cerebrospinal fluid biomarkers and tau ligand positron emission tomography are promising biomarkers of PSP. A multidisciplinary approach to meet the patients' complex needs is the current core treatment strategy for this devastating disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.